5-chloromethyl-3-(3-(t-butoxy-carbamoyl)phenyl)-[1,2,4]-oxadiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-chloromethyl-3-(3-(t-butoxy-carbamoyl)phenyl)-[1,2,4]-oxadiazole
• 英文别名: 3-[5-(chloromethyl)-1,2,4-oxadiazol-3-yl]-N-[(2-methylpropan-2-yl)oxy]benzamide
• 化学式: C₁₄H₁₆ClN₃O₃
• 分子量: 309.752
• InChiKey: QWPMAZSSDIEIAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  77.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  尿素 、 diisopropylethyl amine 、 3-(t-butoxycarbamoyl)benzonitrile 在 4-二甲氨基吡啶 、 NH₂OH 作用下， 以 1,4-二氧六环 、 Et2O-CH2Cl2 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 以70%的产率得到5-chloromethyl-3-(3-(t-butoxy-carbamoyl)phenyl)-[1,2,4]-oxadiazole
  参考文献：
  名称：

  Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use

  摘要：

  二氨基噻唑化合物可调节和/或抑制特定蛋白激酶的活性。这些化合物及含有它们的药物组合物能够介导酪氨酸激酶信号传导，以调节和/或抑制不需要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。

  公开号：

  US20020025976A1

文献信息

• DIAMINOTHIAZOLES AND THEIR USE FOR INHIBITING PROTEIN KINASES
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：EP1181283B1

  公开（公告）日：2005-02-02
• US6620828B2
  申请人：——

  公开号：US6620828B2

  公开（公告）日：2003-09-16
• [EN] DIAMINOTHIAZOLES AND THEIR USE FOR INHIBITING PROTEIN KINASES<br/>[FR] DIAMINOTHIAZOLES ET LEUR UTILISATION POUR INHIBER LES PROTEINES KINASES
  申请人：AGOURON PHARMA

  公开号：WO2000075120A1

  公开（公告）日：2000-12-14

  Diaminothiazole compounds of formula (I) that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
• Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US20020025976A1

  公开（公告）日：2002-02-28

  Diaminothiazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  二氨基噻唑化合物可调节和/或抑制特定蛋白激酶的活性。这些化合物及含有它们的药物组合物能够介导酪氨酸激酶信号传导，以调节和/或抑制不需要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。